PlainPatent
USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Neopharm Co., Ltd.

USPTO PatentsView assignee record - 17 granted patents across 9 technology areas, recorded in grant years 2015–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61K (Preparations FOR Medical, Dental OR Toiletry Purposes).

RSS updates for this company
Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Neopharm ranks #17,024 of 49,997 tracked US assignees by granted-patent volume, with 17 patents across 9 technology areas.

#17,024
of 49,997 US assignees by volume
Top 23%
by Innovation Score (45.4/100)
7.9
avg claims per patent
+13%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R17024 · Foreign Corporation #17,024 · 17 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-SPARSE · TYPE-FRNCORP · VEL-UP · BOOK-FULL

  • GRANTS-MICRO 17 grants
  • MID-PACK #17,024/49,997
  • PHOTO-FINISH Navitor Pharmaceutic…
  • CPC-NARROW A61K · 9 areas
  • INNOV-PAR 45.4/100
  • CLAIMS-SPARSE 7.9 claims/avg
  • TYPE-FRNCORP Foreign Corp
  • VEL-UP +13% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Navitor Pharmaceuticals, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Neopharm’s 45.4 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around Neopharm

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Neopharm's Innovation Score is 45.4/100 (top 23% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for Neopharm?

Each dot is one of Neopharm’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Neopharm’s own 7.9 claims/patent is at or below the 19.9 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Neopharm vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 16.916.91717.1 510152025 Granted patents (volume) Avg claims / patent Navitor Pharmaceuticals, Inc. - 17, 11.94Navitor Pharmaceu…Nemo Power Tools Ltd - 17, 6.12Nemo Power ToolsNeo4j Sweden AB - 17, 19.94Neo4j Sweden ABNeograft Technologies, Inc. - 17, 22.47NeograftNeptune Subsea IP Limited - 17, 21Neptune Subsea IPNetzyn, Inc. - 17, 12.29NetzynNew Health Sciences, Inc. - 17, 21New Health Scienc…Nexmo, Inc. - 17, 21.29NexmoNeopharm Co., Ltd. - 17, 7.94Neopharm
Neopharm vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Neopharm's grants concentrate

Neopharm Co., Ltd. is a focused PatentsView assignee: 9 CPC subclasses with 82.4% of grants classified under A61K (Preparations FOR Medical, Dental OR Toiletry Purposes). Peak complete grant year is 2022 (5 grants) versus a trough of 1 in 2016. By volume, Neopharm sits between Navitor Pharmaceuticals, Inc. and Nexmo, Inc..

Neopharm's three-year grant acceleration

Neopharm Co., Ltd. shows 7 grants in 2022–2024 against only 2 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Neopharm's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Neopharm holds 17 patents at rank #17,040, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Neopharm

By rank, the assignees closest to #17,040 in granted patent volume.

Leaders in A61K (Preparations FOR Medical)

Other assignees with the most granted patents in Neopharm's primary technology class.

Neopharm's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

45 Top 23% higher than 77% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0123456 20152016201720182020202120222023 2
USPTO utility patent grants by year · 2015–2023

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Neopharm Co., Ltd. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 2 11.8%
2016 1 5.9%
2017 3 17.6%
2018 2 11.8%
2020 1 5.9%
2021 1 5.9%
2022 5 29.4%
2023 2 11.8%

Which technologies does Neopharm Co., Ltd. patent most?

Top 9 of 9 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Neopharm Co., Ltd.'s patent record in context - here's where to go next.

  • Neopharm Co., Ltd.'s lead technology class is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes), 82.4% of its portfolio - see every assignee active in that class. Explore A61K
  • Ranked #17,024 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Neopharm Co., Ltd. against Navitor Pharmaceuticals, Inc., an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 45.4/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.